Pressmeddelande

Devyser wins Norwegian tender for Devyser CFTR at Oslo University Hospital

Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital for the supply of Devyser CFTR, the company’s advanced genetic testing kit designed for screening sequence variants implicated in cystic fibrosis (CF). The tender represents an indicative order value of around 1,1m SEK over the one-year period.

This win strengthens Devyser’s footprint in the Nordic region and supports the expansion of high-quality, fast, and reliable CFTR testing within established national newborn screening programs. Cystic fibrosis is one of the most common genetic disorders in Europe, with a prevalence of 1 in 2000–3000 newborns*, depending on the region. Early detection is essential, and genetic testing plays a central role in confirming CF diagnoses, identifying carriers, and enabling clinicians to understand the specific CFTR variants involved.

“This tender win shows the trust placed by Oslo University Hospital in Devyser’s CFTR assay to support Norway’s commitment to aid early CF detection and improved pediatric care” said, Jan Wahlström, CEO, Devyser.

“This year we have seen a lot of positive development in Norway with Q3 YTD revenues tripling compared to 2024. I’m pleased to see yet another incremental deal closed in a market poised for increased growth” said Theis Kipling, CCO Devyser.

About Devyser CFTR
Devyser CFTR is an NGS test used in the confirmation of cystic fibrosis and screening of genetic variants in newborns and adults. Devyser CFTR NGS captures all clinically relevant cystic fibrosis gene mutations in a single assay that is purpose-designed for fast and efficient lab processing.

^{* Santos V, Cardoso AV, Lopes C, Azevedo P, Gamboa F, Amorim A. Cystic fibrosis - Comparison between patients in paediatric and adult age. Rev Port Pneumol (2006). 2017 Jan-Feb;23(1):17-21. doi: 10.1016/j.rppnen.2016.07.002. Epub 2016 Oct 13. PMID: 27743767.}

About Devyser
Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency. 

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes. 

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US. 

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio. 

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company´s Certified Adviser is Redeye AB. 

Discover how we're shaping the future of lab diagnostics at www.devyser.com. 